Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
8-K
Black Diamond Therapeutics Announces Changes to Board of Directors
11 Apr 24
S-8
Registration of securities for employees
12 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
12 Mar 24
8-K
Departure of Directors or Certain Officers
18 Jan 24
8-K
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
4 Jan 24
8-K
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
13 Dec 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
6 Nov 23
8-K
Black Diamond Therapeutics Announces CEO Transition
18 Sep 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
11 Aug 23
8-K
Entry into a Material Definitive Agreement
30 Jun 23
424B5
Prospectus supplement for primary offering
30 Jun 23
424B5
Prospectus supplement for primary offering
29 Jun 23
8-K
Regulation FD Disclosure
27 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
16 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
9 May 23
ARS
2022 FY
Annual report to shareholders
4 Apr 23
DEFA14A
Additional proxy soliciting materials
4 Apr 23
DEF 14A
Definitive proxy
4 Apr 23
S-8
Registration of securities for employees
9 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
8-K
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
9 Mar 23
8-K
Black Diamond Therapeutics Announces Changes to Board of Directors
19 Dec 22
8-K
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
12 Dec 22
EFFECT
Notice of effectiveness
23 Nov 22
CORRESP
Correspondence with SEC
18 Nov 22
UPLOAD
Letter from SEC
17 Nov 22
S-3
Shelf registration
14 Nov 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
9 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 22
Latest ownership filings
4
Shannon Campbell
12 Apr 24
4
Prakash Raman
12 Apr 24
3
Shannon Campbell
12 Apr 24
3
Prakash Raman
12 Apr 24
4
Ali Behbahani
3 Apr 24
4
WENDY L DIXON
3 Apr 24
SC 13G/A
T. Rowe Price Investment Management, Inc.
11 Mar 24
4
Fang Ni
15 Feb 24
4
Brent Hatzis-Schoch
15 Feb 24
4
Sergey Yurasov
15 Feb 24
4
Elizabeth Buck
15 Feb 24
4
Mark A. Velleca
15 Feb 24
4
Erika Jones
15 Feb 24
SC 13G
T. Rowe Price Investment Management, Inc.
14 Feb 24
SC 13G/A
BB BIOTECH AG
13 Feb 24
4
Ali Behbahani
15 Dec 23
4
WENDY L DIXON
15 Dec 23
SC 13D/A
Versant Venture Capital VI, L.P.
9 Nov 23
4
BIOTECH AG BB
19 Oct 23
4
Ali Behbahani
18 Sep 23
4
Mark A. Velleca
18 Sep 23
4
WENDY L DIXON
18 Sep 23
4
Rajeev M. Shah
7 Jul 23
4
Ali Behbahani
6 Jul 23
4
BIOTECH AG BB
3 Jul 23
4
BIOTECH AG BB
29 Jun 23
4
David M. Epstein
28 Jun 23
144
Notice of proposed sale of securities
27 Jun 23
4
Ali Behbahani
16 Jun 23
4
WENDY L DIXON
16 Jun 23
4
Mark A. Velleca
16 Jun 23
4
Ali Behbahani
17 May 23
4
Alexander Mayweg
17 May 23
4
Rajeev M. Shah
17 May 23
4
Mark A. Velleca
17 May 23
4
Garry E Menzel
17 May 23
4
Samarth Kulkarni
17 May 23
4
WENDY L DIXON
17 May 23
4
Kapil Dhingra
17 May 23
4
Ali Behbahani
20 Mar 23